16-15-01





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No: 27866/36470A



# PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. 1.53

Box Patent Application Commissioner for Patents Washington, D.C. 20231

J	ı	1	

Transmitted herewith for filing is the patent application of

Inventor(s):

Donald E. Stauton

Title:

MATERIALS AND METHODS TO MODULATE LIGAND BINDING/ENZYMATIC ACTIVITY OF  $\alpha\beta$  PROTEINS CONTAINING AN ALLOSTERIC REGULATORY SITE

## 1. Type of Application

$\boxtimes$	This	is a	new	application	for	â
-------------	------	------	-----	-------------	-----	---

□ utility patent.

☐ design patent.

This is a continuation-in-part application of prior application no.

### 2. Application Papers Enclosed

1 Title Page

146 Pages of Specification (excluding Claims, Abstract, Drawings & Sequence Listing)

8 Page(s) of Claims

1 Page(s) of Abstract

1 Sheet(s) of Drawings (Figs. 1 to 2)

☐ Formal

7 Page(s) of Sequence Listing

### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on October 12, 2001, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EL 564 463 415 US.

oseph A. Williams, Jr. (Reg. No. 38,65

3.	Declara	tion or (	Oath				
			Enclose	ed			
		,		Execute	ed by (c	heck all applicable bo	xes)
					Invento	or(s)	
					-	epresentative of inven R 1.42 or 1.43)	itor(s)
							wing a proprietary interest on ed to sign or cannot be reached
							d by 37 CFR 1.47 and the by 37 CFR 1.47 are enclosed. for fee.
		⊠		tion on			agent is authorized to file this An executed declaration will
4.	Small E	intity St	atus				
		Applica	ant claims small entity status. See 37 CFR 1.27.				
			A smal	l entity	stateme	ent is(are) attached.	
5.	Additio	nal Pap	ers Encl	osed			
			Prelimi	nary Am	nendmer	nt	
			Inform	ation Di	sclosure	: Statement	
			Declar	ation of	Biologic	al Deposit	
		⊠	•	iter read acid se		ppy of sequence listing	g containing nucleotide and/or
			Microf	iche con	nputer p	program	
			Associ	ate Pow	er of A	ttorney	
			Verifie	d transla	ation of	a non-English patent a	application
			An ass	ignment	t of the	invention	
			Reque	st and C	ertificat	ion Under 35 U.S.C.	122(b)(2)(B)(i)
		$\boxtimes$	Return	receipt	postcar	rd	
			Other				

Certified copies of applications from which priority under 35 USC 119(e) is claimed are listed below and

- is not attached.
- □ will follow.

APPLICATION NO.	FILED
60/239,750	12 October 2000

# 7. Filing Fee Calculation (37 CFR 1.16)

# A. Utility Application

CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
 	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE				\$370.00	,	\$740.00
TOTAL	49 -20	= 29	X 9 =	\$261	X 18 =	\$
INDEP.	6 - 3	= 3	X 42 =	\$126	X 84 =	\$
⊠ First Pre Claim	sentation of Multip	ole Dependent	+ 140 =	\$140	+ 280 =	\$
			Filing Fee:	\$897	OR	\$

В.		Design Application (\$165.00/\$330.00) Filing Fee:	\$_	
C.		Plant Application (\$255.00/\$510.00) Filing Fee:	\$_	
D.	Other F	ees		
		Recording Assignment [Fee \$40.00 per assignment]	l	\$
		Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refuto sign or cannot be reached [Fee \$130.00]	used	\$
		Other		\$

**Total Fees Enclosed** 

## 8. Method of Payment of Fees

☐ Enclosed check in the amount of:
☐ Charge Deposit Account No. 13-2855 in the amount of:

\$

\$897.00

☐ Not enclosed

# 9. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-2855. A copy of this Transmittal is enclosed.

Please refund any overpayment to Marshall, Gerstein & Borun at the address below.

#### 10. Correspondence Address

Customer No.: 04743

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6402 (312) 474-6300 (312) 474-0448 (Telefacsimile)

By:

Joseph A. Williams, Reg. No. 38,689

October 12, 2001

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Staunton et al. CERTIFICATE OF MAILING BY **EXPRESS MAIL** "EXPRESS MAIL" mailing label Application Serial No.: To be No. EL564463415US determined Filed: Herewith Date of Deposit: October 12, 2001 I hereby certify that this paper and the For: MATERIALS AND METHODS TO MODULATE LIGAND documents referred to herein as enclosed BINDING/ENZYMATIC ACTIVITY herewith are being deposited with the OF ALPHA/BETA PROTEINS United States Postal Service "EXPRESS CONTAINING AN ALLOSTERIC MAIL POST OFFICE TO ADDRESSEE" REGULATORY SITE service under 37 C.F.R. §1.10 on the date indicated above and are addressed to the Commissioner for Patents, Washington, Group Art Unit: To be determined D.C. 20231. Examiner: To be assigned

STATEMENT UNDER 37-C.F.R. §1.821 and §1.825

Commissioner for Patents Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821and §1.825, respectively are the same and include no new matter.

Respectfully submitted,

Ву

oseph A. Williams, Jr. (Reg. No. 38,659)

MARSHALL, GERSTEIN & BORUN

6300 Sears Tower

233 South Wacker Drive Chicago, Illinois 60606-6402

(312) 474-6300

October 12, 2001